A number of studies have reported that patients with schizophrenia have a higher body
mass index (BMI) than the general population. Few Asian studies have examined BMI in …

The aim of the present study was to investigate the relationship between 10 psychotropic
agents and worsening BMI from overweight to obesity among inpatients with schizophrenia …

Background: Patients with severe mental illness have higher cardiovascular mortality and
shortened life span; this is at least partly attributed to medications although lifestyle plays a …

Patients suffering from schizophrenia have an elevated risk for obesity and metabolic
syndrome due to multiple factors, including antipsychotic drug consumption. Diet and …

Background: Weight gain is a common side effect of clozapine treatment and may expose
patients to obesity-associated health risks. We proposed that concomitant treatment with an …

This investigation estimates and compares, for the first time, the distribution of body mass
index (BMI: kg/m2) and the prevalence of obesity among Chinese outpatients with …

Background: High dietary saturated fat (SF) intake is strongly linked to metabolic
disturbances. The goal of this study was to understand the relationship between clozapine …

Background: The prevalence of schizophrenia is increasing every year. Schizophrenia also
causes other problems because of the risk of experiencing malnutrition. The study aims to …

Clozapine and olanzapine caused the largest increases in bodyweight in men with
schizophrenia, according to a study conducted in the US. Data was obtained from 92 men …

OBJECTIVE: Clozapine is associated with significant weight gain. However, it is still
debatable whether the majority of weight gain occurs in the early phase of treatment or if …